Crestor Presentation
ADA & ACC Consensus Statement Lipoprotein Management in Patients with Cardiometabolic Risk Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine.
A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to PCSK9, SAR236553/REGN727, in Patients with.
Novel Therapeutic Target of PCSK9
LCAT
Clinicaltrials no. NCT01288443
